Progressive Supranuclear Palsy Treatment Market Is Expanding Rapidly As Alzprotect Entered Into A Partnership With PAREXEL Biotech To Perform The Clinical Phase 2a Development Of AZP2006 For The Treatment Of PSP

 

Progressive Supranuclear Palsy Treatment Market

Progressive Supranuclear Palsy is a condition of temporarily paralyzed muscles in the face, hands, and feet. It is usually caused by an accident or injury to one of the central nervous system nerves or the spinal cord. When this condition is left untreated, it can result in permanent disability. The cause of the disorder is unknown, although a variety of causes have been proposed including genetic anomalies, neurological problems, tumors, and brain defects. In most cases, however, the disorder is idiopathic.

Rising incidence of progressive supranuclear palsy (PSP) is expected to drive growth of the global progressive supranuclear palsy treatment market. PSP is one of the rarest and undiagnosed disorders and hence it is difficult to know how many people are affected. According to the National Organization for Rare Disorders (NORD), around 20,000 people in the U.S. are affected by PSP with as many as 5-7 in 100,000. According to the same source, the onset of this disorder occurs between 45 and 75 years of age, with the average age of onset being 65 years. As a result of this demand for PSP, treatment has increased significantly. Hence, these factors are expected to drive growth of the global progressive supranuclear palsy treatment market. Furthermore, continuous R&D activities and trials for treatment PSS are expected to propel the global progressive supranuclear palsy treatment market growth in the near future.

Lack of knowledge regarding diagnosis PSP and inadequate research and development is expected to hinder the global progressive supranuclear palsy treatment market growth in the near future. Among regions, North America is expected to witness significant growth in the global progressive supranuclear palsy treatment market. This is owing to the presence of robust and state-of-the-art neural research facilities in the U.S. and Canada. Furthermore, Europe is expected to register a robust growth rate, owing to the presence of major market players such as Novartis AG, GlaxoSmithKline, and more.

Key players involved in the global progressive supranuclear palsy treatment market are Novartis AG, GlaxoSmithKline, AbbVie Inc., TauRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Asceneuron Therapeutics, Biogen Inc., AlzProtect, Bristol-Myers Squibb Co.,  UCB Biopharma, Merck & Co. Inc., and TauRx Pharmaceuticals.

For instance, in March 2019, AlzProtect, a biopharmaceutical company, partnered with PAREXEL Biotech, a subsidiary of PAREXEL International Corporation, to perform the clinical phase 2a development of AZP2006 for the treatment of PSP.

Comments

Popular posts from this blog

Cfmoto Has Announced The Launch Of Its Electric Concept ATV To Expand Its Business In The Global All-Terrain Vehicle (ATV) Lighting Systems Market

Increasing Demand for Processed Food and Initiatives to Challenges Assumptions about Monosodium Glutamate to Augment Growth of Monosodium Glutamate Market

Increased Adoption of Catamarans for Various Applications to Augment the Powered Catamaran Market Growth